Showing results (11-20 of 1,948) with videos related to
Sort By:
Pageof 195
Diabetologia|April 1, 1991
The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patientsR W James, D PomettaInternational Journal of Clinical Pharmacology and Biopharmacy|December 1, 1979
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofenH Micheli, D Pometta, A GustafsonLa Nouvelle Presse Medicale|December 22, 1980
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]H Micheli, D Pometta, A GustafsonSchweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|October 9, 1990
[Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment]U Keller, A Golay, D PomettaDiabetologia|December 1, 1981
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy menM Stalder, D Pometta, A SuenramBiochimica Et Biophysica Acta|April 26, 1989
Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gelsR W James, A Proudfoot, D PomettaHelvetica Paediatrica Acta|January 1, 1981
[High-density lipoproteins in children with coronary diseases]I Oberhänsli, D Pometta, H Micheli, et al.The Journal of Endocrinology|January 1, 1987
Interference of dimethyl alpha-(dimethoxyphosphinyl) p-chlorobenzyl phosphate (SR-202) in thyroid hormone metabolism: evidence of inhibition of monodeiodinationC Liniger, D Pometta, A G BurgerSchweizerische Medizinische Wochenschrift|December 16, 1989
[Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]I Borghini, R W James, D PomettaSchweizerische Medizinische Wochenschrift|December 17, 1983
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]A Suenram, D Pometta, N von der WeidPageof 195